Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

Zhejiang University

Overview

The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Hepatocellular Carcinoma

Interventions

SorafenibDRUG

S-1DRUG

OxaliplatinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hepatocellular carcinoma after liver transplantation * Major organ (heart, lung and brain) function was normal Exclusion Criteria: * Any active infectious process * The presence of clinically confirmed extrahepatic metastasis * Postoperative dysfunction of any organ

Locations (1)

First affiliated hospital, Zhejiang University

Hangzhou, China

Outcomes

Primary Outcomes

Time to Recurrence (TTR)

Time to Recurrence

Time frame: within five years after liver transplantation

Secondary Outcomes

Overall survival (OS)

Overall survival

Time frame: within the five years after liver transplantation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.